GlassScriptPhysician profile
Maimoona Bahlol
NPI 1447771746
$1,182.45
in general payments reported to CMS, 2019-2025
14 companies · $627 in 2025
The $627 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $68.99 · 2023: $286 · 2024: $201 · 2025: $627.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,113.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,113.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $274.63 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Medtronic, INC. | $214.95 | 2022-2025 | Minimed 780g |
| Lilly USA, LLC | $180.29 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Insulet Corporation | $111.13 | 2022-2025 | Omnipod |
| Beta Bionics, INC. | $80.72 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Sequel Med Tech, LLC | $64.79 | 2025 | Twiist |
| Dexcom, INC. | $59.49 | 2022-2025 | Dexcom G6 Transmitter |
| Corcept Therapeutics | $50.59 | 2025 | Korlym |
| Boehringer Ingelheim Pharmaceuticals, INC. | $33.21 | 2024-2025 | Jardiance, Synjardy |
| Mannkind Corporation | $30.99 | 2025 | |
| Abbott Laboratories | $23.65 | 2023 | Freestyle Libre 2 |
| Tandem Diabetes Care, INC. | $23.32 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Xeris Pharmaceuticals, INC. | $20.40 | 2023 | Gvoke Hypopen |
| Pfizer INC. | $14.29 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maimoona Bahlol listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.